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Background: It has been a decade since the complex fractionated atrial electrograms (CFAEs) were ﬁrst
established following the publication of Nademanee's standards. However, the status and focus of CFAE research
are unclear, as is the efﬁcacy of additional CFAE ablation in atrialﬁbrillation (AF). This literature review andmeta-
analysis were designed to determine the status of CFAE research and the efﬁcacy and complications of CFAE ab-
lation alone, pulmonary vein isolation (PVI) alone and PVI plus CFAE ablation in AF.
Methods:With the assistance from reference librarians and investigators trained in systematic review, we con-
ducted a literature search of MEDLINE (via PubMed), Embase, the Cochrane Library, ScienceDirect, Wiley Black-
well and Web of Knowledge, using “complex fractionated atrial electrograms” for MeSH and keyword search.
Results: The literature on CFAEs increased from2007,mainly focusing onmapping studies, withmechanism stud-
ies increasing signiﬁcantly from 2012. Fifteen trials with 1525 patients were qualiﬁed for our meta-analysis. Suc-
cess rates were as follows. Overall (P b 0.001): CFAE ablation alone, 23.5–26.2%; PVI, 64.7%; PVI plus CFAE
ablation, 67.0%. Single ablation: PVI, 60.4%; PVI plus CFAEs, 68.8% (OR 1.53, 95% CI 1.07–2.20, P = 0.02). Re-
ablation: PVI, 69.0%; PVI plus CFAEs, 77.2% (OR 1.54, 95% CI 1.06–2.24, P = 0.02). Paroxysmal AF: PVI, 76.7%;
PVI plus CFAEs, 79.1% (OR 1.20, 95% CI 0.79–1.81, P = 0.39). Persistent or permanent AF: PVI, 47.9%; PVI plus
CFAEs, 58.7% (OR = 1.59, 95% CI 1.13–2.24, P = 0.008). Complication rates: PVI, 2.6%; PVI plus CFAEs, 3.4%
(OR 1.22, 95% CI 0.58–2.57, P= 0.61).
Conclusions: In the literature, CFAEmapping studies precededmechanism studies. CFAE ablation alone is insufﬁ-
cient for the treatment of AF. Additional CFAE ablation after adequate PVI or PVI plus linear ablation improves the
outcome of single ablation and re-ablation without increasing complications, especially in persistent or perma-
nent AF. There are insufﬁcient data to support a similar improvement in paroxysmal AF or inducible AF after
PVI for paroxysmal AF.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).AF; NPAF, non-paroxysmal AF;
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and Ltd. This is an open access article1. Introduction
Radiofrequency catheter ablation (RFCA) procedures for atrial ﬁbril-
lation (AF) are well established in the management of symptomatic,
drug-refractory AF. Pulmonary vein isolation (PVI) alone, as the corner-
stone of RFCA, is typically sufﬁcient to treat patients with paroxysmal
AF, though it is less than optimal for persistent AF [1,2]. Additional abla-
tion targeting complex fractionated atrial electrograms (CFAEs) as the
AF substrate may be necessary in patients with persistent AF [3–5].
The CFAEs are deﬁned as a fractioned atrial electrograms comprising
two or more deﬂections with continuous baseline activity or an atrial
electrograms with cycle length (CL) ≤ 120 ms [6]. CFAEs are unlikely
to be rapid drivers; they may represent other phenomena that facilitateunder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Continuous fractionation or rapid, regular “rotor-like” electrograms,
both locally and at distant atrial sites, are due to a wider activation of
the cardiac neural network [9]. Some researchers have reported that
targeting ganglionated plexi (GP) eliminated these areas of continuous
fractionation, both locally and at distant sites [9,10]. Thus far, the effect
of CFAE ablation on prognosis is unclear. The aimof this studywas to de-
termine the effects of PVI (both circumferential PVI [CPVI] and pulmo-
nary vein antrum isolation [PVAI]) alone, CFAE ablation alone and PVI
plus CFAE ablation (or CFAEs plus PVI) on the prognosis of different
types of AF.
2. Material and methods
2.1. Study selection
We classiﬁed AF according to a recent consensus statement as fol-
lows: paroxysmal AF–recurrent AF that terminates spontaneouslywith-
in 7 days; persistent AF–AF that is sustained beyond 7 days or lasts less
than 7 days but necessitates pharmacologic or electrical cardioversion.
Includedwithin the category of persistent AF is “longstandingpersistent
AF”, which is deﬁned as continuous AF of more than 1 year duration
[11].
To identify and retrieve all potentially relevant studies reporting the
procedure, outcome or success rate of PVI, PVI combined with CFAE ab-
lation and CFAE ablation alone in AF, we conducted a literature search
with the assistance of librarians and investigators trained in systematic
review procedures inMEDLINE (via PubMed), Embase, the Cochrane Li-
brary, ScienceDirect, Wiley Blackwell andWeb of Knowledge. MEDLINE
was searched for abstractsﬁrst, using theMedical SubjectHeading “atri-
al ﬁbrillation” and PubMed was searched for “complex fractionated
electrograms”. The Embase search used a similar strategy. The Cochrane
Library, ScienceDirect, Wiley Blackwell and Web of Knowledge were
searched for abstracts using the keywords “complex fractionated elec-
trograms”. A manual check of the reference lists of all accepted studies
and of recent reviews andmeta-analyses was performed to supplement
the above searches and ensure optimal and complete literature retriev-
al. After deleting duplicated abstracts, we obtained 399 references,
which we used to determine the status and focus of CFAEs studies
(Fig. 1).
Randomized controlled trials (RCTs) and matched controlled trials
(MCTs) were included in our meta-analysis. Mapping studies, mecha-
nism studies, reviews, meeting reports, comments, case reports, ab-
stracts only, meta-analyses, systematic reviews, articles not in English
and other clinical abstracts were excluded (Fig. 2). Non-surgical studies
involving ablation were included. The searchwas conducted on January
1, 2014. Study qualitywas assessedusing amodiﬁed version of the qual-
ity assessment criteria for MCTs [12]. Data were collected on paper ex-
traction forms by one investigator and independently veriﬁed by a
second investigator. Discrepancies were reviewed by the two investiga-
tors and, when necessary, by the entire group. Most discrepancies in
data extraction involved the assigning of ablation techniques. When
the technique was unclear or when the investigators could not agree
on a particular data variable, the authors of the study were contacted
for clariﬁcation.
2.2. Statistical analysis
Review Manager 5 was used to synthesize the data. Differences in
categorical outcomes among ablation groups were reported as odds
ratio (OR) with 95% conﬁdence interval (95% CI) using a ﬁxed or ran-
dom effect model. Differences in adverse events associated with the
procedure among groups were reported as ORs with 95% CIs using a
ﬁxed effect model. The presence of heterogeneity between trials was
assessed by the chi-squared (χ2) statistic and the extent of inconsisten-
cy was assessed using the I2 statistic. Heterogeneity was consideredsigniﬁcant if the P value was less than 0.1. Publication bias was evaluat-
ed using funnel plots. All tests were two-tailed with a P value of less
than 0.05 as the level of statistical signiﬁcance.
3. Results
3.1. Search and analysis of literature
We searched several databases and obtained 915 references, all of
which we imported into Medical Citation Manager 3.0 (Jin Ye Tian
Sheng Corporation, China); after deleting duplicated references, we
identiﬁed 399 unique references (Fig. 1). The literature on CFAEs
increased from 2007, mainly focused ﬁrst on mapping studies and
then on mechanism studies, which increased signiﬁcantly from 2012
(Fig. 2). Fifteen publications were identiﬁed that met our meta-
analysis inclusion criteria. The basic characteristics of these 15 studies
are presented in Table 1. The included studies were published in
2004–2012 and comprised 10 single-center and ﬁve multicenter stud-
ies, 10 RCTs and ﬁve MCTs. The size of the enrolled patient population
ranged from 35 to 119. Five and six studies reported outcome data sole-
ly for paroxysmal AF or persistent AF, respectively.
3.2. Patient characteristics
The 15 studies included a total of 1525 patients. Themean age of the
patients ranged from 52 to 62 years (Table 1). All studieswere predom-
inantly of male subjects (1127/1525, 73.9%), with the proportion of
males ranging from 63% to 88%. Mean left atrium (LA) diameter was
34–49 mm and mean left ventricular ejection fraction (LVEF) was
45–66%. The percentage of enrolled patients with hypertension was
42.0% (487/1159), though four studies did not report this information.
The percentage of patients with other cardiac conditions was 30%;
these included coronary disease, valvular disease, history of cardiac sur-
gery, hyperthyroidism, heart failure, structural heart disease and con-
genital heart disease. Three studies did not report this information.
Only one study estimated the CHADS2 score. Three studies (Andrade
13]; Chen [14]; Verma [15]) reported the number of patients with a his-
tory of stroke, which was 3.4% (11/317). According to their inclusion
criteria, most of the studies focused on symptomatic and drug-
refractory AF or high-burden AF. The details of the studies' inclusions
were symptomatic and refractory AF or high burden AF, including par-
oxysmal, persistent and permanent AF. The exclusion criteria included
AF secondary to reversible cause; left atrial thrombus; previous abla-
tion; inadequate anticoagulation; LA N 55 mm; pregnant; coronary
artery bypass graft surgery within 12 months; LVEF b 35%; valvular
disease; prosthetic heart valves; myocardial infarction, cardiac surgery
or stroke within 3 months; congenital heart disease; allergy to contrast
media; contraindication to warfarin; age b 18 years; and hyperthyroid-
ism. The mean duration of follow-up was 8–23 months. Methods
of follow-up included 24 h, 48 h or 7 day Holter monitoring,
transtelephonicmonitoring, implanteddevices, event recorder, external
loop recorder and symptomatic 12-lead electrocardiography (ECG). Six
studies deﬁned the primary end point as no atrial tachycardia (AT) or AF
lasting N30 s [13–17] and three studies deﬁned the primary endpoint as
no AT or AF lasting N1 min [18–20] according to the Holter monitoring,
symptomatic ECG or event recording. The other studies deﬁned the pri-
mary end point as no recurrence of AF, AT or atrial ﬂutter (AFL) [21–26].
One study did not deﬁne a primary end point [27].
3.3. Catheter ablation
The mapping systems used in these studies were the NavX and
CARTO systems. Seven studies used NavX only and two CARTO
only; ﬁve studies used both NavX and CARTO. One study did not re-
port whichmapping systemwas used. CFAEs were deﬁned according
to Nademanee's standard. The deﬁnition of CFAEs was simpliﬁed as
Fig. 1. Flow diagram of the trial selection process.
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deﬁned as an averaged interval of 50–120 ms. The study of Gi-
Byoung Nam's group used highly fractionated or continuous electro-
grams with little isoelectric baseline. The 2009 study of Oral [27] de-
ﬁned a CFAEs as CL≤ 120ms or shorter than the AFCL in the coronary
sinus (CS) or electrograms exhibiting fractionation or continuous
electrical activity. The 2011 study of Chen [14] did not report any
deﬁnition of CFAEs except for that according to the mapping system.
Four studies provided overall outcome data for mixed cohorts of any
type of AF. Six studies assessed the efﬁcacy of CPVI/PVAI, CPVI/PVAI
plus CFAEs and CFAEs alone. Four studies assessed PVAI/CPVI and
PVAI/CPVI plus CFAEs. Two studies assessed PVAI and CFAEs plus
PVAI. One study assessed CPVI plus linear ablation and PVI plusCFAEs, CPVI plus linear ablation, and CPVI plus linear ablation and
CFAEs. One study assessed CFAEs plus PVAI and CFAEs.
Through transseptal access, circular mapping and ablation catheters
were advanced into the LA and the anatomyof the LA, PVs and CS recon-
structed using themapping system. In PVAI groups, isolationwas usual-
ly performed in the PVs at the PV antrum–LA junction wherever PV
potentials were recorded. The end point of the procedure was electrical
isolation of all PVs, achieving entry block [16,17,19–21,23,24,27,28]. In
CPVI groups, circumferential radiofrequency lesions were placed using
a wide antral approach outside the PV ostia with the goal of complete
isolation of all four PVs [13–15,18,25]. The end point of CPVI was a com-
plete disappearance of PV potentials or dissociated PV potentials on LA
electrograms. In CFAE ablation groups, if patients with paroxysmal AF
Fig. 2. Distribution of literatures associated with CFAEs. The symbols and abbreviations are the same as those in Fig. 1.
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without isoproterenol using a standardized protocol. CFAE mapping
using an automated algorithm was performed in the LA, CS and right
atrium (RA) using the ablation catheter [13]. Regions with CFAEs were
ablated in the LA, RA and CS, except in the 2009 study of Lin, which
did not include the RA in CFAE ablation [18], and the CFAE ablation of
Verma , which was restricted to the LA septum and anterior LA wall
[24]. In CPVI/PVAI plus CFAE groups, following the completion of the
CPVI/PVAI procedure, mappingwas performed during AF (spontaneous
or induced) to identify regions with CFAEs, which were then ablated. In
the studies of Elayi , Estner and Verma, CFAE ablation was performed
ﬁrst, followed by completion of PVAI ablation [17,20,23]. In patients of
non-paroxysmal AF, if AF is persistent after a routine ablation including
ablating AT or AFL effectively, pharmacological (propafenone or
ibutilide) or electrical cardioversion was taken. The time interval be-
tween the ﬁrst ablation and the repeat ablation ranged from 2 to
6 months.
3.4. Drug therapy
In patients with persistent AF, all anti-arrhythmic drugs (AADs) ex-
cept amiodarone were discontinued for at least ﬁve half-lives. Amioda-
rone was maintained until the day of the procedure or discontinued
8 weeks or 6 months before the procedure. In patientswith paroxysmal
AF, AADswere discontinued except for amiodarone, whichwas stopped
for at least ﬁve half-lives, 4 weeks or 2–6 months before the procedure.
In studies that enrolled patients with persistent AF and paroxysmal AF,
AADs were discontinued for at least ﬁve half-lives except amiodarone,Table 1
Characteristics of participants in the trials.
Study, year Design Centers PAF NPAF Mapping
system
Ablation strategies
Group 1 Gro
Andrade 2012 RCT 8 64 36 NavX CPVI CPV
Gi-Byoung Nam 2012 MCT 1 70 0 NavX CPVI CPV
Chen 2011 RCT 1 118 0 NavX CPVI CPV
Elayi 2011 RCT 1 0 98 NavX PVAI PVA
Estner 2011 RCT 1 0 116 CARTO/NavX CPVI + linear PVI
Verma 2010 RCT 8 64 36 NavX CPVI CPV
Lin 2009 MCT 1 0 60 NavX CPVI + linear CPV
Di Biase 2009 RCT 6 103 0 CARTO/NavX PVAI PVA
Oral 2009 RCT 1 0 119 CARTO PVAI PVA
Deisenhofer 2009 RCT 1 98 0 CARTO/NavX PVAI PVA
Elayi 2008 RCT 5 0 97 CARTO/NavX PVAI CFA
Estner 2008 MCT 1 0 77 CARTO/NavX NO CFA
Verma 2008 MCT 3 21 14 NavX PVAI CFA
Verma 2007 MCT 1 40 60 NO PVAI PVA
Oral 2004 RCT 1 100 0 CARTO CPVI CPVwhich was stopped at least 8 weeks or 3–5 months before the proce-
dure. Warfarin was used to maintain the international normalized
ratio (INR) at 2.0–3.0 (or INR N 1.8 in Korea) for at least 4 weeks until
the day before the procedure, or was stopped 2 days before admission
and replaced by intravenous heparin in cases with INR b 2.0 in persis-
tent AF. During the ablation procedure, heparinwas used tomaintain ef-
fectively activated clotting time, ranging from 250 s to 400 s. In most
studies, warfarin was administrated for 3 months to 12 months (INR
2.0–3.0), except for 3 days in the study of Gi-Byoung Nam.
3.5. PVI vs PVI plus CFAE ablation vs CFAE ablation
Four studies including 259 patients evaluated the efﬁcacy of CFAE
ablation and PVI (Fig. 3). The overall success ratewas 26.2% for CFAE ab-
lation and 64.7% for PVI. PVIwas superior to CFAE ablation (OR 0.19, 95%
CI 0.07–0.50, P= 0.0008). The heterogeneity among these studies was
signiﬁcant (χ2 = 8.83, P= 0.03, I2 = 66%). Five studies of 364 patients
provided outcome data on PVI plus CFAE ablation and CFAE ablation
(Fig. 4). Overall success rates were 67.0% for PVI plus CFAEs and 23.5%
for CFAEs alone (OR 8.46, 95% CI 5.04–14.21, P b 0.00001). The hetero-
geneity among these studies was not signiﬁcant (χ2 = 6.32, P= 0.18,
I2 = 37%).
3.6. PVI vs PVI plus CFAE ablation
Twelve studies including 1165 patients demonstrated that PVI plus
CFAEs had a signiﬁcantly higher success rate (68.8%; Fig. 5) than PVI
(60.4%) for single ablation (OR 1.53, 95% CI 1.07–2.20, P = 0.02). TheFollow up
(months)
Repeat
ablation
Primary end point
up 2 Group 3
I + CFAEs CFAEs 12 NO No AT N 30 s
I + CFAEs NO 23 ± 12 YES No AF/AT off AADs
after 3 months
I + CFAEs CFAEs 22.6 ± 6.4 NR No AT N 30 s off AADs
I + CFAEs NO 17.2 ± 5.2 NO No AF
+ CFAEs NO 12 YES No AT off AADs
I + CFAEs CFAEs 12 YES No AT N 30s after 12 months
I + linear + CFAEs NO 19 ± 11 YES No AF N 1 min
I + CFAEs CFAEs 13.7 ± 2.2 YES No AF/AT N 1 min
I + CFAEs NO 10 ± 3 YES No AT N 30 s off AADs
after 12 weeks
I + CFAEs NO 19 ± 8 YES No AT N 30s
Es + PVAI NO 16 YES No AF/AT N 1 min
Es + PVAI CFAEs 13 ± 10 YES No AF N 30 s
Es + PVAI NO 13 ± 4 NO No AF after 2 months off AADs
I + CFAEs NO 12 NO No AT
I + CFAEs NO 8 ± 2 NO No AF after 6 weeks
Fig. 3. The success rate of CFAE ablation vs. PVI ablation.
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0.04, I2 = 44%). Funnel plot analysis suggested that there was no publi-
cation bias (Fig. 6). Eight studies underwent reablation. In Di Biase's
study [19], only 7 patients of PVAI and PVAI plus CFAEs recurrent AF ac-
cepted reablation, six of them demonstrated no further AF. The ablation
strategies of Estner [22] didn't estimate the effect of PVAI only. Thus, the
six studies were enrolled, including 603 patients. The result showed
that, in patients who underwent PVI plus CFAE ablation in whom AF re-
curred (Fig. 7), re-ablation had a high success rate that tended toward a
signiﬁcant statistical difference compared with PVI alone (OR 1.54, 95%
CI 1.06–2.24, P= 0.02). Success rates for PVI plus CFAEs and PVI were
77.2% (234/303) and 69.0% (207/300). The heterogeneity was not sig-
niﬁcant (χ2 = 8.74, P= 0.19, I2 = 31%). In patients with paroxysmal
AF, there was no signiﬁcant difference between PVI and PVI plus
CFAEs in the proportion of patients who were free from AF after treat-
ment (OR 1.20, 95% CI 0.79–1.81, P= 0.39). Success rates for PVI plus
CFAEs and PVI alone were 79.1% and 76.7%, respectively. The heteroge-
neity was not signiﬁcant (χ2 = 9.76, P= 0.13, I2 = 39%) (Fig. 8). The
studies of Verma [24], Deisenhofer [16], Di Biase [19], Verma [15],
Chen [14] and Gi-Byoung Nam [26] investigated paroxysmal AF but
failed to show that PVI plus CFAEs was superior to PVI alone. Oral
(2004) [25] randomized patients to receive additional CFAE ablation
or not, if AF remained after CPVI, but the additional CFAE ablation did
not achieve a better success rate (Fig. 9). The same result was obtained
by Chen [14] for additional CFAE ablation in patientswith AF induced by
rapid atrial pacing after CPVI. In patients with persistent or permanent
AF, PVI plus CFAE ablation had a success rate of 58.7%, whichwas better
than that of PVI at 47.9% (OR= 1.59, 95% CI 1.13–2.24, P= 0.008). The
heterogeneity was not signiﬁcant (χ2 = 9.42, P = 0.15, I2 = 36%)
(Fig. 10).
3.7. Complications
Ten studies reported the complications of PVI plus CFAE ablation and
PVI. The complication rate of PVI plus CFAEswas3.4%,whichwas similar
to that of PVI at 2.6% (OR 1.22, 95% CI 0.58–2.57, P = 0.61). I2 was 0%,
indicating no signiﬁcant heterogeneity between PVI plus CFAE ablationFig. 4. The success rate of PVI plus Cand PVI (χ2= 3.30, P= 0.86, I2= 0%) (Fig. 11). Adverse events includ-
ed cardiac tamponade, hemothorax, pseudoaneurysms, PV stenosis and
the need for pacemaker implantation due to persistent sinus node dys-
function after ablation.
4. Discussions
4.1. Main ﬁndings
The literature on CFAEs increased from 2007, mainly focusing ﬁrst
on mapping studies, followed by mechanism studies, which increased
signiﬁcantly from 2012. PVI plus CFAE ablation achieved better out-
comes, not only for single ablation but also for re-ablation. PVI plus
CFAE ablation is the advised strategy for persistent or permanent AF,
but not for paroxysmal AF. There are insufﬁcient data to demonstrate
that additional CFAE ablation is needed for paroxysmal AF, even for AF
induced by rapid atrial pacing after PVI. Additional CFAE ablation after
PVI did not signiﬁcantly increase complications. CFAE ablation alone is
not an advised strategy for any type of AF, with a signiﬁcantly low suc-
cess rate of less than 27%.
4.2. Decade review of CFAEs
PV ablation has gradually developed into the cornerstone of treat-
ment for AF, especially symptomatic and paroxysmal AF [29,30].
Nademanee's ﬁrst deﬁnition of CFAEs has been used to guide AF abla-
tion with a relatively high success rate [6]. CFAE ablation together
with PVI, multilinear lesions and autonomic modiﬁcation or stepwise
ablation is the strategies used for persistent AF [31]. In the past decade,
CFAEmechanisms and the use of CFAEs as hotspots have been explored
in theﬁeld of electrophysiology. Themechanisms of CFAEs are related to
anatomic and electrical tissue heterogeneity (such as microstructural
obstacles [32]), zones with slow conduction or collisions, pivot points
at the end of functional blocks during AF [7,33], and the autonomic ner-
vous system [34,35], especially the GPs close to PVs [9,36,37]. Thus far,
mechanism studies weremainly published in 2012 and lag signiﬁcantly
behind mapping studies, the numbers of which increased from 2007.FAE ablation vs. CFAE ablation.
Fig. 5. The success rate of PVI vs. PVI plus CFAEs in a single ablation.
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of targeting CFAEs is debated, while therapeutic strategies remain to be
exploited [38]. Although new algorithms for mapping CFAEs are contin-
ually being developed, they have not yet been used clinically [38–40].
CFAEs have been hypothesized to represent disorganized passive acti-
vation deriving fromdistant drivers, at least in some patients, but the ef-
ﬁcacy of CFAE ablation is debated [41,42]. It is important to develop new
mapping algorithms distinguishing between passive and active activa-
tion; the latter may be the source of drivers or rotors that maintain AF.
4.3. CFAE ablation as an insufﬁcient strategy
A study has shown that, following one session of CFAE ablation
alone, 65% of patients with paroxysmal AF, 54% with persistent AF and
45% with permanent AF were free from AF, though some of these pa-
tients were administered nifekalant, which suggests that, in a high per-
centage of these patients, the CFAE ablation terminated the AF without
isolating the PVs [43]. The studies of Di Biase [19], Verma [15], Chen [14]
and Andrade [13] suggest that CFAE ablation alone has a smaller impact
on AF recurrence during 12–22 month follow-up than PVI alone. The
success rate was 26.2% for CFAE ablation alone, compared with 64.7%
for PVI alone. Adding the study of Estner [22] to the above four studies,
PVI plus CFAEs was superior to CFAE ablation alone, with success rates
of 67.0% and 23.5%, respectively. These studies included patients with
paroxysmal AF and persistent AF. Thus, PVI or PVI plus CFAE ablation
may be the advised strategy for AF and not CFAE ablation alone, which
has a lower success rate and requires more repeat procedures, possibly
due to fewer PVs per patient being isolated [15]. CFAE ablation alone re-
sults in high rates of early and late recurrence (3–12 months post-Fig. 6. Funnel plot of studies enrolling in Fig. 5.procedure), whereas CFAEs plus PVI had an increased long term success
rate without an increase in early recurrence of AT [45].
4.4. Cautious additional CFAE ablation for paroxysmal AF
The anatomic characteristics of the PVs, the vicinity of which con-
tains abundant GPs or autonomic nerve axons, means that they can eas-
ily harbor drivers or an active focus due to increased automaticity or
triggered activity [44]. Thus PVI is the cornerstone of AF therapy, espe-
cially for paroxysmal AF. PVI plus CFAEs tended to be superior to PVI
for single ablation, with success rates of 68.8% and 60.4%, respectively.
In patients with recurrent AF, re-ablation also tended to have a higher
success rate in those who underwent PVI plus CFAEs compared with
PVI alone (77.2% and 69.0%, respectively). Does any type of AF (i.e. par-
oxysmal or persistent AF) beneﬁt from PVI alone or PVI plus CFAEs? On
subgroup analysis, there were insufﬁcient studies to conclude that par-
oxysmal AF can beneﬁt from PVI plus CFAEs compared with PVI alone;
the success rates of these two strategies were similar at 79.1% and
76.7%, respectively. The reason was speculated to be that more CFAEs
are located at the PV ostia in paroxysmal AF and thus PVI (especial
wide PV ablation) may have eliminated most of the CFAEs [45]. There
were also insufﬁcient data to demonstrate that additional CFAE ablation
for AF induced by rapid atrial pacing after PVI further increased the suc-
cess rate, though the small scale study of Deisenhofer [16] reported that
patients with paroxysmal AF (25/28) who had inducible AF after PVAI
seemed to beneﬁt from additional CFAE ablation on long term follow-
up (19 ± 8 months). Thus, at present, PVI alone may be the advised
strategy for paroxysmal AF. Whether CFAE ablation in addition to PVI
is advised for AF induced by drugs or rapid atrial pacing after PVI is de-
batable and needs a larger RCT. A randomized study concluded that PVI
plus CFAE ablation was not superior to PVI plus ablation of non-PV trig-
gers or PVI plus empirical ablation at common non-PVAF trigger sites in
paroxysmal AF [46], suggesting that PVI plus non-PV trigger ablation
may be advised rather than additional CFAE ablation, which may
cause damage to larger areas. Thus, patients with inducible AF or non-
PV triggers after PVI seem to beneﬁt from non-PV trigger ablation, the
success rate of which resembles that of additional CFAE ablation on
long term follow-up (N12 months) [49]. To evaluate the efﬁcacy and
beneﬁt of non-PV trigger ablation or additional CFAE ablation in parox-
ysmal AF patients with AF induced by rapid atrial pacing or drugs after
PVI, more and larger randomized studies are needed.
4.5. Selective additional CFAE ablation for persistent and permanent AF
Compared with paroxysmal AF, CFAEs in persistent AF are located
more extensively and uniformly, with more in the posterior wall,
which necessitates more extensive ablation [45,47]. According to
Fig. 7. The success rate of PVI vs. PVI plus CFAEs in reablation.
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CFAE ablation is the advised strategy, with a success rate of 58.7%.
Extensive ablation of CFAEs may eliminate or isolate some of these
high dominant frequency sites, decrease tissue anisotropy by micro-
scar formation or ﬁbroblast proliferation, and reduce anatomic com-
plexity by reducing zones of slow conduction or zones prone to func-
tional conduction block or the number of re-entrant wavelets to the
pivot point [33,48]. In some patients, the prognosis is better if maximal
CFAEs and dominant frequency gradients are present at the boundary or
center of a maximal dominant frequency region [49]. Areas of CFAEs
may represent healthy tissuewith normal atrial voltage and conduction
velocity during normal sinus rhythm [50]. Thus, how large an area of
CFAEs and which type of CFAEs (positive or passive activation) must
be ablated in persistent AF is debated. Shannon's entropy mapping
may be useful for objectively and automatically identifying CFAE sites
for AF ablation [51]. If the AF is not terminated by the procedure or by
at least two procedures with stepwise ablation, electrical cardioversion
at a lowdeﬁbrillation threshold is needed,which restores andmaintains
sinus rhythm for some duration in a proportion of patients [52]. A study
has proposed that restoration to sinus rhythmbefore ablation for persis-
tent AF, whenever possible, decreased the extent of ablationwith a sim-
ilar clinical efﬁcacy [53]. Achievement of sinus rhythm as an end point
using a sequential ablation approach for persistent or permanent AF is
associated with the highest long term success rate, compared with AT
or AF at the end of the procedure [54,55]. To limit the extent of the ab-
lated area, PVI should be performed before targeting CFAEs when a
combined approach is pursued. In a recent report of 5 year follow-up,
the single and multiple ablation success rates for longstanding persis-
tent AF were 20% and 45%, respectively [56]. Most of the patients with
longstanding persistent AF that was terminated via AT had a higher
AT recurrence rate during the follow-up period [60], which means
that further studies of mapping technologies are needed to increase
the success rate.
4.6. Complications of additional CFAE ablation
The complication rate of PVI plus CFAE ablation was similar to that
of PVI alone, at 3.4% and 2.6%, respectively. The most commonFig. 8. The success ratecomplications were cardiac tamponade and persistent sinus node dys-
function after ablation requiring pacemaker implantation. The incidence
of cerebral thromboembolism after PVI ranges from 2% to 14%. This is no
greater than that for PVI after additional CFAE ablation or PVI plus CFAE
ablation, whichwas 7.0%. Multivariate analysis has shown that low LVEF
and concomitant coronary angiography are important predictors of new
cerebral thromboembolism [57]. In another study reporting long term
follow-up for more than 3 years, the incidence of late adverse events as-
sociated with CFAE ablation, including stroke, was only 0.3% per year
[58]. Thus, additional CFAE ablation after PVI does not increase the com-
plications during ablation or post-procedure.
4.7. Comparison with previous researches and meta-analyses
Nademanee's study was the earliest study for CFAE ablation. They
gave more large area ablation than RCTs or MCTs mentioned in our
paper. Most of patients were actively ablated CFAEs around the pulmo-
nary veins (66/120 cases), whichmay reach the end point of pulmonary
vein isolation. Due to more large area ablation of CFAEs, even around
pulmonary vein, high success rate may be reasonable reached. RCTs
and MCTs in our paper, most of CFAEs ablation was underwent guiding
with mapping system; the ablated area was not particularly around the
pulmonary veins. This may be the reason of the lower success rate of
CFAE ablation only, and thus need to combinewith pulmonary isolation
or other ablation strategies [6]. The Kong groupmeta-analyzed six RCTs
comparing PVI with PVI plus CFAE ablation, including four studies of
paroxysmal AF and two studies of persistent AF. The primary outcome
was freedom from AF or AT after a single ablation, with or without
AADs, at N3 month follow-up. Although additional CFAE ablation signif-
icantly increased procedural, ﬂuoroscopy and radiofrequency energy
application times, PVI plus CFAE ablation increased the rate of freedom
fromAF after a single procedure. This study did not evaluate risk/beneﬁt
or efﬁcacy on long term follow-up [59]. In our analysis, the mean du-
ration of follow-up exceeded 12 months, except in the studies of Oral
(8–10 months) [25,27]. Even if we exclude these two studies, we obtain
the same results as above. The meta-analysis of Li [5], including seven
trials (four RCTs and threeMCTs), concluded that CFAE ablation in addi-
tion to standard PVAI increased the long term (10–19 months) successfor paroxysmal AF.
Fig. 9. Study designs for evaluating the effects of additional CFAE ablation in paroxysmal AF. RAP: rapid atrial pacing; R, randomized control study; M, matched control study; one arrow,
one ablated strategies was superior to the other, comparing PVI and PVI plus CFAE ablation; double arrow, one ablated strategies was not superior to the other (with no signiﬁcant differ-
ence), comparing PVI and PVI plus CFAE ablation.
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did not confer any additional beneﬁt in paroxysmal AF. Zhang's meta-
analysis of 15 trials (nine RCTs and six MCTs, follow-up 3–19 months)
demonstrated that adjunctive cardiac autonomic denervation including
CFAE/GP ablation plus PVI signiﬁcantly increased the rate of freedom
from recurrence of AF in both paroxysmal and non-paroxysmal AF
patients. However, cardiac autonomic denervation was not superior to
PVI [60]. Substrate modiﬁcation by additional CFAE ablation is contro-
versial in paroxysmal AF. Wu's systematic review and meta-analysis
including 11 trials (seven RCTs and four MCTs) showed that adjunctive
CFAE ablation conferred additional beneﬁt for non-paroxysmal AF but
not for paroxysmal AF after a single procedure, with an increased
rate of untraceable AT post-procedure [61]. The RCTs in the above
meta-analyses, including that of Oral [25], excluded some patients
who did not have inducible AF after CPVI plus linear ablation in the
posterior LA and mitral isthmus. Thus, the efﬁcacy of CPVI may be
underestimated, overstating the role of adjunctive CFAE ablation in par-
oxysmal AF [25]. In Zhang's analysis, the study of Katritsis [62] was in-
cluded; this randomized 67 patients to PVI or GP plus PVI, which
involved wider areas of ablation and injury to greater amounts of nor-
mal atrial tissue, and suggested that GP plus PVI was superior to PVI,
but did not evaluate the effect of wider GP ablation on atrial function
or the beneﬁt/risk ratio [62]. Thus, wider CFAE or GP ablation for parox-
ysmal AF should be selected cautiously. In our analysis, we evaluated
the beneﬁt of single ablation and re-ablation and the risks related to ad-
ditional CFAE ablation, including complications. Although we obtained
similar success rates for paroxysmal and persistent AF, we provideFig. 10. The success rate for pmore details on study design, baseline characteristics, drug therapy
and procedures. We sought a therapeutic strategy for inducible AF
after PVI, but the available information is limited. Our ﬁndings will
help operators to determinewhich strategy should be used for different
types of AF and to predict the procedural risks.
4.8. Clinical implications
This literature review will help cardiologists understand the status
and focus of CFAE research. Treatment of persistent or permanent AF
is the most difﬁcult and unclear area in clinical practice, though map-
ping algorithms and mechanism studies are developing. Additional
CFAE ablation after PVI achieves better outcomes for single ablation or
re-ablation, especially in persistent or permanent AF, and does not in-
crease complications. There are insufﬁcient data to support a similar im-
provement in paroxysmal AF, even for AF induced by rapid atrial pacing
after PVI. CFAE ablation alone for any type of AF is insufﬁcient and not
advised.
4.9. Study limitations
This study has several limitations. The studies included in the analy-
sis had small numbers of patients and selected study populations; the
patients enrolled had symptomatic, drug-refractory, high-burden par-
oxysmal, persistent or permanent AF. Several studies enrolled patients
with hypertension or other cardiac diseases, but with normal LVEF.
Most of the studies gave no CHADS2 scores, which means we couldersistent/permanent AF.
Fig. 11. The complications of PVI plus CFAEs and PVI.
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points and durations of follow-up, various different methods were
used for follow-up, includingHoltermonitoring, ECG and implanted de-
vices, and some patients were administered oral AADs. It is difﬁcult to
evaluate success rate or outcome over a certain period time without
the same method of follow-up, and to determine the inﬂuence of drug
therapy. In addition, there may have been publication or “ﬁle drawer”
bias, which favors the publication of studies showing an improvement
in outcomes. There were also different control populations, such as
PVAI, CPVI or CPVI plus linear ablation. Five of the 15 studies were
MCTs with signiﬁcant limitations in study quality, thereby conferring
some risk of bias. Signiﬁcant heterogeneity was identiﬁed, though the
lack of adequate publications limits opportunities for more detailed
analyses.
5. Conclusions
Mapping studies have been followed by mechanism studies in CFAE
research. CFAE ablation alone is not an advised strategy for any type of
AF. Additional CFAE ablation after adequate PVI or PVI plus linear abla-
tion improves the outcome of single ablation and re-ablation without
increasing the rate of complications related to the procedure, especially
in persistent or permanent AF. There are insufﬁcient data to support a
similar improvement in paroxysmal AF or in inducible AF after PVI for
paroxysmal AF. Further research is needed to exploit the mechanisms
of and new mapping technologies for CFAEs, and a more detailed RCT
is required to evaluate the efﬁcacy of additional CFAE ablation in clinical
practice.
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